Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial, J Clin Oncol, vol.33, pp.1438-1483, 2015. ,
, Loi n°99-447 Du 9 juin 1999 visant à garantir le droit à l'accès aux soins palliatifs. JORF n° 132 du 10 juin, 1999.
Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med, vol.363, pp.733-775, 2010. ,
, Pittsburgh: National Consensus Project, 2009. www. nationalc onse nsus proj ect. org
Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care, J Clin Oncol, vol.30, pp.1310-1315, 2012. ,
American Society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology, J Clin Oncol, vol.30, pp.1715-1739, 2012. ,
FOLFIRINOX improves survival in patients with metastatic pancreatic Cancer, N Engl J Med, vol.364, pp.1817-1842, 2011. ,
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial, Lancet Oncol, vol.14, pp.490-499, 2013. ,
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial, Lancet Oncol, vol.15, pp.819-847, 2014. ,
Cancer of the pancreas: esmo Clinical Practice guidelines, Ann Oncol, vol.26, issue.5, pp.56-68, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01810223
Biliary cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.27, issue.5, pp.28-37, 2016. ,
Gastric Cancer: esmo clinical Practice guidelines, Ann Oncol, vol.27, issue.5, pp.38-49, 2016. ,
Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, vol.5, pp.649-56, 1982. ,
Discrete Sequential Boundaries for clinical trials, Biometrika, vol.70, pp.659-63, 1983. ,
A multiple testing procedure for clinical trials, Biometrics, vol.35, pp.549-56, 1979. ,
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt, Stat Med, vol.30, pp.2409-2430, 2011. ,
, , 2017.